PASE scores may be used as a marker of therapeutic response. The PASE questionnaire is a valid and reliable tool to screen for active PsA among individuals with psoriasis. PASE was sensitive-to-change with therapy PASE scores were significantly lower for PsA individuals after systemic therapy ( p < 0.034).
Furthermore, 13 of the 15 items demonstrated significant test–retest reliability as assessed by Pearson correlation coefficient ( r ≥ 0.5). A PASE total score of 44 was able to distinguish PsA from non-PsA participants with 76% sensitivity and 76% specificity.
The PsA group had a median Total score of 51 (25th and 75th percentile 44 and 57), and non-PsA group had a median total score of 34 (25th and 75th percentile 21 and 49) ( p < 0.001). PASE total scores ranged from 15 to 74 (possible range, 15–75). Of the 190 participating in the study, 19.5% (37/191) participants were diagnosed with PsA. Receiver operator curves were constructed to optimize sensitivity and specificity for the diagnosis of PsA. The PASE questionnaire was readministered to a subset of individuals with PsA in order to assess test–retest reliability and sensitivity-to-change. The 15-item PASE questionnaire was administered to 190 individuals with either psoriasis or PsA. To meet this need, we have developed the psoriatic arthritis screening and evaluation (PASE) questionnaire. There is a need to screen early for this condition to prevent damage.
0 kommentar(er)
